Fig. 5From: Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysisMedian OS of patients with TP53m AML treated with IC (A), HMA (B), or VEN + HMA (C). *IQR was reported. AML, acute myeloid leukemia; CI confidence interval; HMA, hypomethylating agent; IC, intensive chemotherapy; IQR, interquartile range; NA, not reported; NR, not reached; OS, overall survival; TP53m, TP53-mutated; VEN, venetoclaxBack to article page